Weishi anti-epileptic new drug Perampanel (Weiketai) has been approved by the State Drug Administration

Recently,, Aisya's anti-epilepticnew drug(http://Perampanel(Weiketai) was approved by the State Drug Administration for the use of adults and children 12 years and older with partial seizures (accompanied or not accompanied by secondary full-blown seizures)About The PyrumpanayThe Bolpananai is a pioneering anti-epileptic tablet developed by the Tsukuba Research Center and is taken daily orallyPhorempanai is a highly selective, non-competitive AMPA receptor antagonist, which can reduce the overexcitement of neurons associated with seizures by targeting the inhibition of glutamate activity of the synaptic after-membrane AMPA receptor, thus achieving the goal of preventing and treating epilepsyHe was approved by the U.SFDA(http://in 2012, becoming the first non-competitive AMPA receptor antagonist to be approved for marketingAt this stage, the approved indications include the addition of the treatment of epilepsy partial seizures (accompanied or not accompanied by secondary all-round seizures) and the addition of treatment to patients aged 12 and over with epilepsy with a primary all-round strong direct seizureTo date, The Company has been approved for listing in more than 60 countries around the worldThe studythe percentage changes of the frequency of seizures per 28 days during treatment in the 4mg, 8mg, 12mg and placebo groups, respectively, compared to baselines, were shown in a randomized, double-blind, parallel, multicenter clinical(http:// , codenamed 335 　　Among them, the 8mg and 12mg groups of The Zolampanai had a statistically significant difference compared to the control group 　　In terms of safety
common adverse reactions to the Pyrpampanay were: dizziness, sleepiness in the Pyrumpanay group, the incidence rate of more than 10%, and more common than the placebo group 　　The incidence of dizziness in the 4mg, 8mg and 12mg groups of The endumpanay was 22.7%, 28.6% and 42.2%, respectively, and the placebo group had 5.7% 　　The drowsiness incidence rates were 15.9%, 17.7% and 17.8% in the 4mg, 8mg and 12mg groups, respectively, and 13.1% in the placebo group